History of any second malignancy in the last  years; subjects with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible; subjects with other malignancies are eligible if they have been continuously disease free for at least  years
History of any other malignancies in the last  years except in-situ cancer, non-muscle invasive bladder cancer, basal or squamous cell skin cancer are eligible
Any other invasive malignancy from which the patient has been disease-free for less than  years with the exception of curatively treated basal or squamous cell skin cancer
History of malignancy other than multiple myeloma within five years of registration, except adequately treated basal or squamous cell skin cancer
Another malignancy excluding basal cell skin cancer
Evidence of any other cancer within the past  years and < % probability of a  year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed).
Any other invasive cancer in the past  years, except basal cell skin
History of malignancy in the last  years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least  years.
Evidence of any other cancer within the past  years and < % probability of a  year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed).
Concurrent malignancy other than Kaposi sarcoma, resectable squamous cell or basal cell skin cancer, or T anal cancer amenable to surgical resection
Evidence of any other cancer within the past  years and < % probability of a  year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed)
Any other malignancy except localized prostate cancer, basal or squamous cell skin cancer, localized cervical cancer or breast cancer that has been curatively treated
Has any other malignancy diagnosed within  years of screening with the exception of basal or squamous cell skin cancer, or non-invasive cancer of the cervix, or any other cancer deemed by the treating physician to be of low-risk for progression or patient morbidity during the study period.
Diagnosis or recurrence of invasive cancer other than the present cancer within  years (except basal or squamous cell carcinoma of the skin that has been definitively treated).
No history of an invasive malignancy (other than this breast cancer, or non-metastatic basal or squamous skin cancers) in the last  years
Subjects must not have history of an invasive malignancy (other than this breast cancer, or non-metastatic basal or squamous skin cancers) in the last  years
Any active cancer diagnosis (basal or squamous cell cancers allowed) within the last  years for which the patient is receiving active therapy or which is untreated; any cancer diagnosis within the last  years that is considered treated and/ or on surveillance may be included in the trial
History of other malignancy within the previous  years, except basal cell or squamous cell carcinoma, or non-muscle invasive bladder cancer.
No prior history of keratoacanthoma (well differentiated squamous cell skin cancer variant, often centrally ulcerated); history of basal cell cancer is allowed
No history of an invasive malignancy (other than this prostate cancer, or non-metastatic basal or squamous skin cancers) in the last  years
Diagnosis of an invasive malignancy within  years (other than current prostate cancer or non-metastatic basal or squamous skin cancers)
No history of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last  years
History of another malignancy in the previous  years, with a disease-free interval of <  years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible.
Previous malignancy other than Colorectal cancer (CRC) in the last  years except for basal cell cancer of the skin or pre-invasive cancer of the cervix
Invasive cancer other than ovarian cancer within  years (except basal or squamous cell carcinoma of the skin that has been definitely treated)
History of previous malignancy (except in-situ cancer or basal or squamous cell skin cancer) within past  years
Concurrent malignancy or a history of previous malignancy treated with curative therapy within the last  months (other than squamous/basal cell cancer of the skin or cervical cancer), for which the survival prognosis is <  years
No concurrent active primary or metastatic cancer other than superficial squamous cell or basal cell skin cancer
history of any other malignancy treated within the last  years, other than squamous or basal cell skin cancer;
Previous history of another cancer within  years, except completely removed basal or squamous cell skin cancer.
Invasive cancer other than ovarian cancer within  years (except basal or squamous cell carcinoma of the skin that has been definitely treated)
Have an additional malignancy diagnosed within  years of study enrollment with the exception of basal or squamous cell skin cancer or cervical cancer in situ.
History of any second malignancy in the last  years; patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible.
History of any second malignancy in the last  years. Patients with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible
Diagnosis or recurrence of invasive cancer other than the present cancer within  years (except basal or squamous cell carcinoma of the skin that has been definitively treated)
A prior cancer diagnosis within the past three years (except basal cell, surgically treated squamous cell skin cancer, early prostate cancer under observation)
History of active malignancy, including basal/squamous cell skin cancer
History of active malignancy in the past  years (excluding basal/squamous cell skin cancer or prostate cancer with a Gleason score  or less)
History of active malignancy within the past  years (excluding basal/squamous cell skin cancer or prostate cancer with a Gleason score  or less)
History of other malignancy =<  years prior to the registration/randomization evaluation, with the exception of basal cell or squamous cell skin cancer
Active malignancy within the past  years (excluding HCC, basal/squamous cell skin cancer, or prostate cancer with a Gleason score  or less)
History of other malignancy =<  years prior to the registration/randomization evaluation, with the exception of basal cell or squamous cell skin cancer
Prior history of invasive cancer within  years of study entry or history of metastatic cancer; exceptions include non-metastatic, curatively treated basal and squamous cell carcinoma of the skin
Any malignancy within  years of baseline; participants with a history of basal cell or squamous cell skin cancer may be enrolled at the discretion of the investigator
History of active co-existing non-prostatic malignancies except basal cell skin cancer or squamous cell skin cancer
Active other malignancy (except basal cell or squamous cell skin cancer) within the last  years
Active other malignancy (except basal cell or squamous cell skin cancer) within the last  years